tirzepatide cardiovascular outcomes trial results july 2025 In patients with type 2 diabetes and atherosclerotic disease, was noninferior to dulaglutide with respect to major cardiovascular events. ⁣ ⁣ Read the full SURPASS-CVOT and Research Summary Effectiveness of semaglutide versus Pharmaceutical Vials:3

tirzepatide cardiovascular outcomes trial results july 2025 In patients with type 2 diabetes and atherosclerotic disease, was noninferior to dulaglutide with respect to major cardiovascular events. ⁣ ⁣ Read the full SURPASS-CVOT and Research Summary Effectiveness of semaglutide versus Pharmaceutical Vials:3

Effectiveness of semaglutide versus control in HbA1c and weight reduction | Download Scientific Diagram

These rates, while not dramatically different from other incretin therapies, contributed to the higher overall discontinuation figures

Pharmaceutical

Vials:3

Injection Site Reactions Both treatments involve injections, which can cause localised swelling or bruising